Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study.
肥胖且無第二型糖尿病個體中,胰高血糖素樣肽-1受體激動劑的長期安全性和療效:一項全球回顧性隊列研究。
Diabetes Obes Metab 2024-08-22
The Possible Effect of the Long-Term Use of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Hba1c and Lipid Profile in Type 2 Diabetes Mellitus: A Retrospective Study in KAUH, Jeddah, Saudi Arabia.
長期使用葡萄糖樣肽-1受體激動劑(GLP-1RA)對沙特阿拉伯吉達的KAUH糖尿病患者HbA1c和脂質檔案的可能影響:一項回顧性研究。
Diseases 2023-03-30
Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase.
GLP-1受體激動劑在減重和安全性方面的差異:來自調節期的非隨機多中心研究。
Prim Care Diabetes 2023-08-01
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis.
肥胖且無糖尿病個體中胰高血糖素樣肽-1受體激動劑對體重和心臟代謝參數的功效和安全性:系統性回顧和荟萃分析。
Endocr Pract 2024-02-06
Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study.
GLP-1 受體激動劑與其他降糖藥物在患有非酒精性脂肪肝和2型糖尿病個體中的心血管和死亡結果:一項大型基於人口的配對队列研究。
Diabetologia 2024-02-14
Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients.
「過重或肥胖非糖尿病患者心血管事件上胰高血糖素樣肽-1受體激動劑的安全性和有效性。」
Curr Probl Cardiol 2024-02-14
Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study.
糖尿病患者中胰高血糖素樣肽-1受體激動劑的有效性和安全性:來自一項回顧性真實世界研究的證據。
Front Endocrinol (Lausanne) 2024-03-27
GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study.
GLP-1受體激動劑用於肥胖但無糖尿病患者的減重:一項關於益害的動態模擬研究。
EClinicalMedicine 2024-06-07
Real world study of GLP-1 receptor agonists in overweight or obese type 2 diabetes by using repeated measurement analysis of variance.
使用重複測量變異數分析的真實世界研究:GLP-1 受體激動劑在超重或肥胖型 2 型糖尿病中的應用。
Medicine (Baltimore) 2024-08-09
Mortality and Serious Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System.
與胰高血糖素樣肽-1受體激動劑相關的死亡率和嚴重不良事件:使用FDA不良事件報告系統的藥物監測研究。
Cureus 2024-09-02
Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the Global Collaborative Network : Author list.
使用與不使用 GLP-1 受體激動劑治療的 2 型糖尿病或僅肥胖患者的系統性疾病比較結果:來自全球合作網絡的回顧性隊列研究:作者列表。
J Endocrinol Invest 2024-09-20